𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I trials in paediatric oncology — the European perspective

✍ Scribed by E. J. Estlin; S. Ablett; D. R. Newell; I. J. Lewis; L. Lashford; A. D. J. Pearson

Publisher
Springer US
Year
1996
Tongue
English
Weight
881 KB
Volume
14
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

✦ Synopsis

The current recommendations for Phase I trials should allow more confident interpretation of the toxicity and efficacy of new agents by providing a framework for multicentre and international co-operation. An overview of the aims and designs of Phase I trials is presented, along with a summary of current and recently published United Kingdom Childrens Cancer Study Group Phase I trials, and a discussion of some of the difficulties faced in the methodology and evaluation of Phase I studies in children.

📜 SIMILAR VOLUMES

Continual reassessment methods in phase
Continual reassessment methods in phase I trials of the combination of two drugs in oncology
✍ Andrew Kramar; Anne Lebecq; Emmanuel Candalh 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

Most phase I trials in oncology use standard methods for treating successive groups of patients with increasing doses in order to determine the maximum tolerated dose (MTD). These methods have been criticized because they treat many patients at suboptimal dose levels, and do not provide an accurate

Phase I trial of trimetrexate in pediatr
Phase I trial of trimetrexate in pediatric solid tumors: A pediatric oncology group study
✍ Pappo, Alberto S. ;Vats, Tribhawan ;Williams, Thomas E. ;Bernstein, Mark ;Kamen, 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 283 KB

## Abstract Trimetrexate (TMTX), a lipophilic antifol, was evaluated in a Pediatric Oncology Group (POG) Phase I trial in children with refractory solid tumors. TMTX was administered intravenously daily × 5 every three weeks. Starting dose was 6.4 mg/m^2^/day. Dose was escalated by 20% until the ma

Phase II trial of taxol in salivary glan
Phase II trial of taxol in salivary gland malignancies (E1394): A trial of the Eastern Cooperative Oncology Group
✍ Jill Gilbert; Yi Li; Harlan A. Pinto; Timothy Jennings; Merrill S. Kies; Paula S 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 1 views

## Background: Malignant tumors of the salivary glands make up approximately 5% of head and neck cancers. the eastern cooperative oncology group (ecog) initiated a phase ii evaluation of paclitaxel in patients with locally recurrent or metastatic salivary gland malignancies. ## Methods: Chemo-nai

Phase II trial of gemcitabine in patient
Phase II trial of gemcitabine in patients with advanced sarcomas (E1797) : A trial of the Eastern Cooperative Oncology Group
✍ Scott Okuno; Louise M. Ryan; John H. Edmonson; Dennis A. Priebat; Ronald H. Blum 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 2 views

## Abstract ## BACKGROUND The current study was conducted to evaluate the antitumor activity and toxicity of gemcitabine in patients with advanced sarcoma. ## METHODS Twenty‐five patients with advanced sarcomas, who previously were untreated for metastatic disease, were treated on an Eastern Coo